Influence of antipsychotic treatment type and regimen on the functionality of patients with schizophrenia

References

• Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophr Res 2010;122:1–23.
   Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1–56.
   PubMed Web of Science ®Google Scholar
• Burns T, Patrick D. Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr Scand 2007;116:403–18.
   PubMed Web of Science ®Google Scholar
• Priebe S. Social outcomes in schizophrenia. Br J Psychiatry Suppl 2007;50:s15–20.
   Google Scholar
• Brissos S, Molodynski A, Dias VV, Figueira ML. The importance of measuring psychosocial functioning in schizophrenia. Ann Gen Psychiatry [Internet]; 2011;10:18. doi: 10.1186/1744-859X-10–18.
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Suarez D, Vieta E, Naber D. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res 2009;108:223–30.
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453–60.
   PubMed Web of Science ®Google Scholar
• Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, et al. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr Res 2009;113:210–7.
   PubMed Web of Science ®Google Scholar
• Bodén R, Sundström J, Lindström E, Lindström L. Association between symptomatic remission and functional outcome in first-episode schizophrenia. Schizophr Res 2009;107:232–7.
   PubMedGoogle Scholar
• Ciudad A, Alvarez E, Bobes J, San L, Polavieja P, Gilaberte I. Remission in schizophrenia: Results from a 1-year follow-up observational study. Schizophr Res 2009;108:214–22.
   PubMed Web of Science ®Google Scholar
• Barnes TRE. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011;25:567–620.
   PubMed Web of Science ®Google Scholar
• Siegel SJ, Irani F, Brensinger CM, Kohler CG, Bilker WB, Ragland JD, et al. Prognostic variables at intake and long-term level of function in schizophrenia. Am J Psychiatry 2006;163:433–41.
   PubMed Web of Science ®Google Scholar
• Petkari E, Salazar-Montes AM, Kallert TW, Priebe S, Fiorillo A, Raboch J, et al. Acute psychopathology as a predictor of global functioning in patients with ICD-10 non-affective psychosis: A prospective study in 11 European countries. Schizophr Res 2011;131:105–11.
   PubMedGoogle Scholar
• Bowie CR, Depp C, McGrath JA, Wolyniec P, Mausbach BT, Thornquist MH, et al. Prediction of real-world functional disability in chronic mental disorders: A comparison of schizophrenia and bipolar disorder. Am J Psychiatry 2010;167:1116–24.
   PubMed Web of Science ®Google Scholar
• Shamsi S, Lau A, Lencz T, Burdick KE, DeRosse P, Brenner R, et al. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res 2011;126:257–64.
   PubMed Web of Science ®Google Scholar
• Hofer A, Baumgartner S, Bodner T, Edlinger M, Hummer M, Kemmler G, et al. Patient outcomes in schizophrenia II: The impact of cognition. Eur Psychiatry 2005;20:395–402.
   PubMed Web of Science ®Google Scholar
• Hofer A, Baumgartner S, Edlinger M, Hummer M, Kemmler G, Rettenbacher MA, et al. Patient outcomes in schizophrenia I: Correlates with sociodemographic variables, psychopathology, and side effects. Eur Psychiatry 2005;20:386–94.
   PubMed Web of Science ®Google Scholar
• González-Blanch C, Perez-Iglesias R, Pardo-García G, Rodríguez-Sánchez JM, Martínez-García O, Vázquez-Barquero JL, et al. Prognostic value of cognitive functioning for global functional recovery in first-episode schizophrenia. Psychol Med 2010;40: 935–44.
   Google Scholar
• Heinrichs RW, Ammari N, Miles A, McDermid Vaz S, Chopov B. Psychopathology and cognition in divergent functional outcomes in schizophrenia. Schizophr Res 2009;109:46–51.
   Google Scholar
• Guo X, Zhai J, Liu Z, Fang M, Wang B, Wang C, et al. Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study. Arch Gen Psychiatry 2010;67:895–904.
   PubMed Web of Science ®Google Scholar
• Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. Psychosocial treatment for first-episode psychosis: A research update. Am J Psychiatry 2005;162:2220–32.
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011;127:83–92.
   PubMed Web of Science ®Google Scholar
• Barnes TR, Curson DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 1994;10:464–79.
   Google Scholar
• Fernández Sánchez A, Pinto-Meza A, Maria Haro J. Comparing the efficacy of long-acting pharmaceutical forms (depot) versus oral forms of the atypical and conventional antipsychotics marketed in Spain for treating patients with schizophrenia. Rev Psiquiatr Salud Ment (English Edition) 2009;2:5–28.
   Google Scholar
• Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res 2007;90:186–97.
   PubMed Web of Science ®Google Scholar
• Schennach-Wolff R, Obermeier M, Seemüller F, Jäger M, Messer T, Laux G, et al. Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale. Acta Psychiatr Scand 2011;123:228–38.
   PubMed Web of Science ®Google Scholar
• Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;101:323–9.
   PubMed Web of Science ®Google Scholar
• Garcia-Portilla MP, Saiz PA, Bousoño M, Bascaran MT, Guzmán-Quilo C, Bobes J. Validación de la versión española de la escala de Funcionamiento Personal y Social en pacientes ambulatorios con esquizofrenia estable o inestable. Rev Psiquiatr Salud Ment 2011;4:9–18.
   PubMed Web of Science ®Google Scholar
• Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. The Clinical Global Impression—Schizophrenia scale: A simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003:16–23.
   Google Scholar
• Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67–74.
   PubMed Web of Science ®Google Scholar
• Val Jiménez A, Amorós Ballestero G, Martínez Visa P, Fernández Ferré ML, León Sanromà M. Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test. [Article in Spanish]. Aten Primaria 1992;10:767–70.
   PubMedGoogle Scholar
• Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, et al. The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70 Suppl 4:1–46; quiz 47–8.
   PubMed Web of Science ®Google Scholar
• Bai YM, Chen TT, Wu B, Hung CH, Lin WK, Hu TM, et al. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 2006;39:135–41.
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287–96.
   PubMed Web of Science ®Google Scholar
• Barnes TRE, Paton C. Antipsychotic polypharmacy in schizophrenia: Benefits and risks. CNS Drugs 2011;25:383–99.
   PubMed Web of Science ®Google Scholar
• Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006;188:122–7.
   PubMed Web of Science ®Google Scholar
• Misawa F, Shimizu K, Fujii Y, Miyata R, Koshiishi F, Kobayashi M, et al. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: A cross-sectional study. BMC Psychiatry 2011;11:118.
   PubMed Web of Science ®Google Scholar
• García B. Functionality as a goal in the treatment of schizophrenia. [Article in Spanish]. Actas Esp Psiquiatr 2002;30:312–25.
   Google Scholar
• Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: Can we resolve the conflict?Psychol Med 2009;39:1591–602.
   PubMed Web of Science ®Google Scholar
• Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006;67 (Suppl 5):3–8.
   PubMed Web of Science ®Google Scholar
• Chakos M, Patel JK, Rosenheck R, Glick ID, Hammer MB, Tapp A, et al. Concomitant psychotropic medication use during treatment of schizophrenia patients: Longitudinal results from the CATIE study. Clin Schizophr Relat Psychoses 2011;5:124–34.
   Google Scholar
• Jin H, Zisook S, Palmer BW, Patterson TL, Heaton RK, Jeste DV. Association of depressive symptoms with worse functioning in schizophrenia: A study in older outpatients. J Clin Psychiatry 2001;62:797–803.
   PubMed Web of Science ®Google Scholar
• Deister A, Marneros A. Prognostic value of initial subtype in schizophrenic disorders. Schizophr Res 1994;12:145–57.
   PubMed Web of Science ®Google Scholar
• Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A. Establishing remission and good clinical functioning in schizophrenia: Predictors of best outcome with long-term risperidone long-acting injectable treatment. Eur Psychiatry 2010;25:220–9.
   PubMed Web of Science ®Google Scholar
• Swanson CL, Gur RC, Bilker W, Petty RG, Gur RE. Premorbid educational attainment in schizophrenia: Association with symptoms, functioning, and neurobehavioral measures. Biol Psychiatry 1998;44:739–47.
   PubMed Web of Science ®Google Scholar
• Flor-Henry P. Influence of gender in schizophrenia as related to other psychopathological syndromes. Schizophr Bull 1990;16: 211–27.
   PubMed Web of Science ®Google Scholar
• Goldstein JM, Tsuang MT, Faraone SV. Gender and schizophrenia: Implications for understanding the heterogeneity of the illness. Psychiatry Res 1989;28:243–53.
   PubMed Web of Science ®Google Scholar
• Dixon L. Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophr Res 1999;35 Suppl:S93–100.
   PubMed Web of Science ®Google Scholar
• Aguilar MC, Gurpegui M, Diaz FJ, de Leon J. Nicotine dependence and symptoms in schizophrenia: Naturalistic study of complex interactions. Br J Psychiatry 2005;186:215–21.
   PubMedGoogle Scholar
• Smith RC, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2002;27:479–97.
   PubMed Web of Science ®Google Scholar
• Winterer G. Why do patients with schizophrenia smoke?Curr Opin Psychiatry 2010;23:112–9.
   PubMed Web of Science ®Google Scholar
• Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S, et al. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: Involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 2005;62:649–59.
   PubMed Web of Science ®Google Scholar
• Wing VC, Bacher I, Sacco KA, George TP. Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status. Psychiatry Res 2011;188:320–6.
   Google Scholar
• Sagud M, Mihaljević-Peles A, Mück-Seler D, Pivac N, Vuksan-Cusa B, Brataljenović T, et al. Smoking and schizophrenia. Psychiatr Danub 2009;21:371–5.
   PubMed Web of Science ®Google Scholar
• Kotov R, Guey LT, Bromet EJ, Schwartz JE. Smoking in schizophrenia: Diagnostic specificity, symptom correlates, and illness severity. Schizophr Bull 2010;36:173–81.
   PubMed Web of Science ®Google Scholar